Valuation
- Market cap
- 5,442,000
- Revenue TTM
- $0
- Net income TTM
- $-6,260,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- -0.08
Trading
- Volume
- 373,800
- Avg volume
- 3,368,622
- Day's range
- $2.86 – $3.34
- Shares out
- 1,695,000
- Stochastic %K
- 87%
- Beta
- 0.24
- Analysts
- —
- Price target
- $200.00
Company profile
Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical s...
Show more
Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. The company was founded in 1996 and is based in Carlsbad, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 760 452 8111
- Website
- https://qlgntx.com
- Address
- 5857 Owens Avenue, Suite 300, Carlsbad, United States
Latest news
No headlines yet.
